Recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) following autologous marrow transplantation in man.
The use of rhGM-CSF following autologous marrow transplantation for lymphoid malignancies was explored in a Phase I-II dose escalation study. rhGM-CSF given as a 2 hour infusion for 14 days was well tolerated at doses up to 240 micrograms/m2/day. At doses of 60 micrograms/m2/day or more, rhGM-CSF appeared to have biologic activity accelerating both neutrophil and platelet recovery.